The latest chatter on Sarepta's (SRPT -3.7%) etiplirsen: Edison Investment Research's Jason Zhang notes that the FDA is now "squarely in the middle of the bull and bear scenarios" for SRPT and says the regulator will make a decision on the company's NDA application for etiplirsen "likely before the end of the year." By contrast, Leerink Swann said last week the company may "need to run a Phase III trial in 2014."
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs